Nivolumab plus cabozantinib (N plus C) vs sunitinib (S) for previously untreated advanced renal cell carcinoma (aRCC): Final follow-up results from the CheckMate 9ER trial.

被引：0
|
作者：
Motzer, Robert J.
Escudier, Bernard
Burotto, Mauricio
Powles, Thomas
Apolo, Andrea B.
Bourlon, Maria T.
Shah, Amishi Yogesh
Porta, Camillo
Suarez, Cristina
Barrios, Carlos H.
Richardet, Martin Eduardo
Gurney, Howard
Kessler, Elizabeth R.
Tomita, Yoshihiko
Bedke, Jens
Rangwala, Fatima A.
Askelson, Margarita
Panzica, Julie
Fedorov, Viktor
Choueiri, Toni K.
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Gustave Roussy, Villejuif, France
[3] Bradford Hill Clin Res Ctr, Santiago, Chile
[4] Queen Mary Univ London, Barts Canc Inst, Canc Res UK Expt Canc Med Ctr, Royal Free Natl Hlth Serv Trust, London, England
[5] NCI, Ctr Canc Res, NIH, Bethesda, MD USA
[6] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Urol Oncol Clin, Mexico City, DF, Mexico
[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[8] Univ Bari Aldo Moro, Bari, Italy
[9] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[10] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil
[11] Oncoclin Grp, Porto Alegre, Brazil
[12] Fdn Richardet Longo, Inst Oncol Cordoba, Cordoba, Argentina
[13] Westmead Hosp, Westmead, NSW, Australia
[14] Macquarie Univ, Westmead, NSW, Australia
[15] Westmead Hosp, Sydney, NSW, Australia
[16] Macquarie Univ, Sydney, NSW, Australia
[17] Univ Colorado, Sch Med, Aurora, CO USA
[18] Niigata Univ, Grad Sch Med & Dent Sci, Niigata, Japan
[19] Eva Mayr Stihl Canc Ctr, Klinikum Stuttgart, Stuttgart, Germany
[20] Exelixis Inc, Alameda, CA USA
[21] Bristol Myers Squibb, Princeton, NJ USA
[22] Brigham & Womens Hosp, Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA USA
[23] Harvard Med Sch, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 5_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.5_suppl.439
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nivolumab plus ipilimumab (N plus I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and subgroup analysis of patients (pts) without nephrectomy
    Albiges, L.
    Tannir, N.
    Burotto, M.
    McDermott, D. F.
    Plimack, E. R.
    Barthelemy, P.
    Porta, C. G.
    Powles, T. B.
    Donskov, F.
    George, S.
    Kollmannsberger, C.
    Gurney, H.
    Grimm, M-O.
    Tomita, Y.
    Castellano Gauna, D.
    Rini, B. I.
    Choueiri, T. K.
    Saggi, S. S.
    McHenry, M. B.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S559 - S560
  • [42] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    LANCET ONCOLOGY, 2022, 23 (02): : 292 - 303
  • [43] Efficacy of avelumab plus axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): extended follow-up results from JAVELIN Renal 101
    Haanen, John
    Larkin, James
    Choueiri, Toni
    Albiges, Laurence
    Rini, Brian
    Atkins, Michael
    Schmidinger, Manuela
    Penkov, Konstantin
    Thomaidou, Despina
    Wang, Jing
    Mariani, Mariangela
    di Pietro, Alessandra
    Motzer, Robert
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 51 - 51
  • [44] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
  • [45] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Tannir, Nizar M.
    McDermott, David F.
    Escudier, Bernard
    Hammers, Hans J.
    Aren, Osvaldo Rudy
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Neiman, Victoria
    George, Saby
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    Grimm, Marc-Oliver
    Amin, Asim
    Tykodi, Scott S.
    Tomita, Yoshihiko
    Rini, Brian I.
    McHenry, M. Brent
    Saggi, Shruti Shally
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Characterization of the benefit-risk profile of nivolumab plus ipilimumab (N plus I) v sunitinib (S) for treatment-naive advanced renal cell carcinoma (aRCC; CheckMate 214).
    Tannir, Nizar M.
    Hammers, Hans J.
    Amin, Asim
    Grimm, Marc-Oliver
    Rini, Brian I.
    Mekan, Sabeen
    McHenry, M. Brent
    Kollmannsberger, Christian K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [47] ASCO-GU: 2-Year Follow-up of the CheckMate-9ER Study: Sustained Treatment Benefit with First-line Therapy of advanced Renal Cell Carcinoma with Cabozantinib plus Nivolumab versus Sunitinib
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (05)
  • [48] Checkmate 214 Post Hoc Analyses of Nivolumab Plus Ipilimumab or Sunitinib in IMDC Intermediate/Poor-Risk Patients with Previously Untreated Advanced Renal Cell Carcinoma (ARCC) with Sarcomatoid Features (SRCC)
    Grimm, Marc-Oliver
    Mcdermott, David F.
    Choueiri, Toni K.
    Motzer, Robert J.
    Frontera, Osvaldo Aren
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Harrison, Michael R.
    Rodriguez-Cid, Jeronimo
    Ishii, Yuko
    Mchenry, Brent
    Rini, Brian I.
    Tannir, Nizar M.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 70 - 71
  • [49] Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
    Tomita, Yoshihiko
    Motzer, Robert J.
    Choueiri, Toni K.
    Rini, Brian I.
    Miyake, Hideaki
    Uemura, Hirotsugu
    Albiges, Laurence
    Fujii, Yosuke
    Umeyama, Yoshiko
    Wang Jing
    Mariani, Mariangela
    Schmidinger, Manuela
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [50] Final prespecified overall survival (OS) analysis of the phase 3 CLEAR trial: 4-year follow-up of lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in patients with advanced renal cell carcinoma (aRCC)
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Grunwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jamie R.
    Goh, Jeffrey C.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Rodriguez-Lopez, Karla
    He, Cixin S.
    Okpara, Chinyere E.
    McKenzie, Jodi
    Choueiri, Toni K.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 72 - 73
12345